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Although health-disparities in women presenting with acute coronary syndrome (ACS) have 41 
received growing attention in recent years, clinical outcomes from ACS are still worse for 42 
women than for men. Women continue to experience higher patient and system delays and 43 
receive less aggressive invasive treatment and pharmacotherapies. Gender- and sex-specific 44 
variables that contribute to ACS vulnerability remain largely unknown. Notwithstanding the sex 45 
differences in baseline coronary anatomy and function, women and men are treated the same 46 
based on guidelines that were established from experimental and clinical trial data over-47 
representing the male population. Importantly, younger women have a particularly unfavorable 48 
prognosis and a plethora of unanswered questions remains in this younger population. The 49 
present review summarizes contemporary evidence for gender and sex differences in vascular 50 
biology, clinical presentation, and outcomes of ACS. We further discuss potential mechanisms 51 
and non-traditional risk conditions modulating the course of disease in women and men, such 52 
as unrecognized psychosocial factors, sex-specific vascular and neural stress responses, and 53 
the potential impact of epigenetic modifications. 54 
 55 
Introduction 56 
Cardiovascular disease (CVD) remains the most common cause of morbidity and mortality in 57 
Europe, accounting for 49% of deaths in women and 40% of deaths in men1. Over the last four 58 
decades, age-adjusted mortality for CVD has continuously declined, however to a lesser extent 59 
in women than in men2. Most intriguingly, recent studies report a significant increase in case 60 
fatality rates of acute coronary syndromes (ACS) in young women <55 years of age, while a 61 
decrease in mortality from coronary artery disease (CAD) has occurred in younger men3-6. 62 
Despite growing evidence demonstrating sex and gender differences in baseline risk factors, 63 
coronary anatomy and function, symptoms presentation, comorbidities, treatment efficacy, and 64 
outcomes of ACS, mechanisms behind these differences are largely unexplored6, 7. These 65 
knowledge gaps are nourished by the persistent underrepresentation of women in 66 
cardiovascular clinical trials and a lack of basic science evidence obtained from female animals 67 
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and cells owing to a manifold refuted concern that inclusion of females will increase variability, 68 
and double sample size and costs8-12. This review provides a summary of contemporary 69 
evidence shedding light on sex and gender differences in the clinical presentation of ACS as 70 
well as in diagnostic accuracy of tests, invasive treatment, pharmacotherapy, and outcomes. 71 
 72 
Sex Differences in Coronary Biology 73 
Women have significantly smaller epicardial coronary arteries than men, even after adjustment 74 
for age, body habitus, and left ventricular mass13. Baseline and hyperemic myocardial blood 75 
flow, as assessed by positron emission tomography (PET), is typically higher in women as 76 
compared to men resulting in a similar global coronary flow reserve (CFR) in men and 77 
women14, 15. Although exact mechanisms are lacking, the smaller diameter of female epicardial 78 
coronary arteries together with their higher baseline myocardial blood flow have been 79 
suggested to result in a significant increase in endothelial shear stress conditions in women16. 80 
Given that low endothelial shear stress has been associated with focal lipid accumulation, 81 
pathologic remodeling, and plaque instability17, it has been hypothesized that higher shear 82 
stress conditions in female coronary arteries may contribute to sex differences in susceptibility 83 
to CAD18. These sex differences might be particularly relevant during premenopausal ages 84 
owing to estrogen-dependent effects on endothelial mediators such as nitric oxide, 85 
prostaglandins, and endothelium-derived hyperpolarizing factor19, 20 (Figure 1). The vascular 86 
actions of estrogen are primarily mediated via estrogen receptor α signaling promoting an anti-87 
inflammatory, low-vascular-resistance phenotype that is protected from CVD21. Estrogen 88 
receptor α-mediated effects are blunted in the absence of estrogen which is consistent with 89 
variations seen in vascular stiffness throughout the lifespan of women22. Importantly, increased 90 
vascular stiffness strongly correlates with blood pressure, diastolic dysfunction, impaired 91 
ventricular coupling, and left ventricular remodeling and is thought to play a role in disease 92 
conditions preferentially affecting postmenopausal women such as heart failure with preserved 93 
ejection fraction (HFpEF) or isolated systolic hypertension23. Finally, women display distinct 94 
coronary plaque characteristics with a more diffuse and non-obstructive disease pattern, 95 
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reduced overall plaque burden, and calcium content as well as less signs of necrosis in the 96 
plaque core24 (Figure 1). Accordingly, while plaque rupture is the primary mechanisms 97 
responsible for myocardial infarction in men, plaque erosion is the major cause of coronary 98 
thrombosis in women, particularly in premenopausal women25, 26 (Figure 2). Despite an overall 99 
lower plaque burden in women, coronary artery calcium scoring has recently been 100 
demonstrated to be a stronger risk predictor for future cardiovascular events in women as 101 
compared to men27. Thus, coronary artery calcium scoring has been recommended for 102 
evaluation of asymptomatic women with a 10-year CVD risk >7.5% by a recent expert 103 
consensus statement28. 104 
 105 
Influence of Sex and Gender on Cardiovascular Risk  106 
Traditional Risk Factors 107 
Although traditional risk factors for CVD are the same in women and men, differences in 108 
prevalence and impact of these risk factors vary between men and women29, 30 (Figure 3). This 109 
is especially seen in ACS, as women who present with ACS are generally older and have more 110 
comorbidities, including a higher prevalence of hypertension, dyslipidemia, diabetes, heart 111 
failure, and atrial fibrillation31, 32. Women with early-onset type 1 and type 2 myocardial 112 
infarction (MI)33 have received growing attention as a group affected by inequalities in health 113 
outcomes4, 34. Mechanisms for these differential outcomes are unclear, but data from the 114 
Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) study 115 
indicate that younger women have a worse pre‐event health status versus men, including lower 116 
overall and mental health qualities of life35. Smoking, like diabetes mellitus, has been shown 117 
to have a stronger impact on women, as there is a 25% increased risk for fatal and non-fatal 118 
cardiovascular events in female smokers as compared to male ones, independent of other risk 119 
factors36-38 (Figure 3). Smoking-related cardiovascular risk was highest among young and 120 
middle-aged women36. Diabetes also carries a differential risk between sexes, with diabetic 121 
women being at significantly higher risk of developing CAD or HFpEF than their male 122 
counterparts39-42 (Figure 3). Finally, a significant role in the case of younger women is also 123 
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played by family history as women <65 years with a maternal history of MI encounter a four 124 
times higher risk of ACS than same aged men or older women43. 125 
 126 
Non-traditional Risk Conditions 127 
Data emerging from the VIRGO study indicate that young and middle-aged women 128 
hospitalized for type 1 and type 2 MI were more likely to have lower socioeconomic status, 129 
higher levels of psychosocial burden, such as depression and poorer physical/mental health, 130 
and overall lower quality of life compared to men44 (Figure 2). Accordingly, depression, trauma, 131 
and perceived stress have been identified as powerful predictors of cardiovascular risk in 132 
young and middle-aged women45, 46. This trend is not surprising, given that psychosocial stress 133 
has substantially increased for women during the last two decades due to a continuous 134 
increase in women’s economic participation and educational attainment47. Further, low 135 
socioeconomic status is an established variable inversely associated with global coronary risk 136 
and imposes a higher excess risk on women as compared to men48 (Figure 2). Of note, recent 137 
work states that feminine roles and personality traits, but not female gender itself, are 138 
associated with higher rates of ACS as compared to masculine characteristics, however, 139 
objective evidence of this vulnerability is still insufficient49. 140 
It is increasingly appreciated that the gut microbiome, harboring trillions of microbial 141 
cells, plays an important role in the development of CAD50-52. Indeed, systemic trimethylamine 142 
N-oxide levels – a pro-atherogenic and pro-thrombotic metabolite produced by the gut 143 
microbiome – was shown to predict 30-day and 6-month event-free survival in women and 144 
men with suspected ACS53, 54. In addition, there is emerging evidence for sex differences in 145 
microbiome-mediated contribution to cardiovascular risk factors and comorbidities including 146 
inflammatory processes, autoimmune disease, cardiometabolic disorders, and major 147 
depression55-57. Men and women have different genetic backgrounds, energy and nutritional 148 
requirements across the lifespan, as well as differences in gastrointestinal transit time, which 149 
can contribute to sex differences in microbiome58. Future studies will show the potential of gut 150 
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microbes to provide novel diagnostic and therapeutic targets tailored to the female and male 151 
cardiovascular system. 152 
 153 
Female-specific Risk Factors 154 
Premenopausal women are thought to be relatively protected against CVD as compared with 155 
age-matched men, with early menopausal transition and postmenopausal status shown to be 156 
associated with adverse risk for CVD and mortality59, 60. Estrogen withdrawal at menopause 157 
has many negative effects on cardiovascular function and metabolism, including alterations in 158 
body fat distribution, endothelial dysfunction, vascular inflammation, sympathetic tone, and a 159 
higher insulin resistance contributing to hypertension, 61, 62. In fact, menopause is accompanied 160 
by an accelerated age-related rise in cardiac and peripheral sympathetic nerve activity, most 161 
likely related to an impaired central modulation of baroreflex function or a direct inhibitory 162 
influence of estrogen on sympathetic nerve activity63, 64. However, although initially supported 163 
by large observational studies65, 66, randomized controlled trials largely failed to show any 164 
cardiovascular benefit of menopausal hormone replacement therapy (HRT) and even 165 
demonstrated an increased event rate in postmenopausal women with a recent ACS67-69. Thus, 166 
the use of HRT for primary and secondary prevention of CVD remains controversial and is 167 
currently not recommended70, 71. However, a re-analysis of the Women’s Health Initiative data 168 
led to the so called ‘timing hypothesis’, indicating that HRT might be beneficial when initiated 169 
during early menopause 72-74 Notably, while these data suggest that specific subgroups of 170 
postmenopausal women might profit from HRT, the use of estrogen-containing contraceptives 171 
in premenopausal women with known CVD is generally not recommended75. In fact, although 172 
the risk is small in absolute numbers, combined oral contraceptives have been associated with 173 
hypertension as well as a significant increase in venous and arterial thrombosis76-78. 174 
Interestingly, changes in iron status have been suggested as an alternative 175 
mechanism accounting for the risk increase seen in postmenopausal women. Indeed, 176 
concurrent but inverse alterations occur between iron and estrogen levels in healthy women 177 
during menopausal transition; whereas estrogen decreases because of the cessation of 178 
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ovarian functions, iron increases as a result of decreasing menstrual period79. Higher iron 179 
plasma levels and associated alterations in iron metabolism after early-onset menopause are 180 
believed to exert detrimental effects on the cardiovascular system via induction of inflammatory 181 
cascades80. Conversely, several observational reports claim that iron deficiency independently 182 
predicts adverse cardiovascular outcome in women and men81-83. Thus, the iron hypothesis 183 
remains controversial owing to the lack of adequately designed clinical trials and the fact that 184 
current biomarkers of iron status are not validated. As iron deposits in the heart tissue might 185 
impact cardiovascular endpoints, T2 star (T2*) cardiac magnetic resonance imaging may offer 186 
an opportunity to improve our mechanistic understanding for the role of iron in CAD84. 187 
Pregnancy is often quoted as providing a glimpse into a woman’s future health status 188 
with numerous pregnancy-related complications associated with increased cardiovascular 189 
risk85. A recent meta-analysis concluded that the risk of CAD was highest in women with a 190 
history of preeclampsia, placental abruption, gestational hypertension, and diabetes86 (Figure 191 
2). Moreover, the development of gestational diabetes has been shown to increase the risk for 192 
CAD by two to three-fold even 25 years after delivery87, while preterm delivery (<37 weeks 193 
gestation) in the first pregnancy was independently associated with a 1.5-fold increased risk 194 
of CAD88. Notably, a combination of these risk factors seems to potentiate cardiovascular risk 195 
as the occurrence of major coronary events and mortality was nearly six-fold increased after 196 
preeclampsia in combination with preterm delivery and/or infants born small for gestational 197 
age89. Accordingly, adding pregnancy complications to traditional risk models led to significant 198 
improvements of CVD risk prediction among a representative sample of Norwegian women90. 199 
 200 
Potential Future Risk Marker: Epigenetic Modifications 201 
Epigenetic modifications of the genome might constitute a novel pathway leading to sexual 202 
dimorphism in ACS. DNA-methylation (DNAm), the best-understood epigenetic modification, 203 
defines cell’s identity, and it is vital for normal cellular processes and adapting cells to 204 
environmental changes91. However, dysregulated DNAm contributes to adverse changes in 205 
gene expression and may affect cardiovascular risk factors including obesity, atherosclerosis, 206 
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inflammation, hypertension, blood lipids, and glucose metabolism, subsequently leading to 207 
increased risk of developing CAD92-94. Although epigenetic mechanisms have emerged as 208 
potential future risk factors in CVD, this field of research is still in a pioneer stage; to date, few 209 
studies with small sample sizes have investigated associations of DNAm with ACS. Of note, 210 
Li D et al. reported that more than 11,000 differentially methylated CpGs exist between ACS 211 
cases and controls, thereby covering 5,071 genes involved in ACS-related biological 212 
processes95. Similarly, differences in DNAm of ANGPTL2, a pro-inflammatory gene, were 213 
found in post-ACS patients as compared to their healthy age-matched controls96. Sex 214 
differences at the level of DNAm and associations of global and gene-specific DNAm with 215 
traditional risk factors have been described, supporting the hypothesis that epigenetic 216 
mechanisms may play a role in shaping sex differences in ACS97-107 (Figure 4). However, 217 
despite epigenetics being increasingly linked to sexual dimorphism in the cardiovascular 218 
system, there is lack of adequately designed epigenetic studies assessing sex-specific effects 219 
of epigenetics in the development of ACS. 220 
 221 
Mental Stress and Myocardial Injury 222 
Recent data indicate that women, especially young women, are particularly vulnerable to the 223 
detrimental associations of mental stress and cardiovascular health108-111 (Figure 2). 224 
Accordingly, women seem to perceive greater psychological stress following an acute type 1 225 
or type 2 MI as compared to men, which, in turn, is associated with worse recovery and 226 
prognosis112. As young women with ischemic heart disease are a group with unexplained high 227 
mortality, these gender differences in mental stress responses are of particular importance and 228 
emphasize the need for a better evaluation of the psychosocial domain in order to risk stratify 229 
these women. The underlying psychological and biological mechanisms accounting for the 230 
adverse vascular response to psychological stress in women are not well understood. Besides 231 
vascular determinants, variation in baseline sympathetic activity and women’s propensity 232 
towards microcirculatory abnormalities110, excess serotonin, a worse overall mental health 233 
status in women35, as well as a differential activation of the limbic system and the 234 
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hypothalamic–adrenocortical axis in men and women are notable. Indeed, women have higher 235 
baseline cardiac sympathetic activity and excessive sympathetic discharge after an acute type 236 
1 MI than men64, 113. Further, a link between the limbic system and long-term cardiovascular 237 
outcomes has recently been demonstrated114 and gender-stratified data indicate that this link 238 
might be pathogenic in women, but not in men115. 239 
 240 
Ischemia and Non-obstructive CAD (INOCA) 241 
Increasing evidence supports the notion that obstructive CAD alone is insufficient to explain 242 
symptoms of myocardial ischemia116. Indeed, microvascular angina, defined as symptoms and 243 
objective evidence of myocardial ischemia along with non-obstructive CAD (<50 % coronary 244 
diameter reduction and/or fractional flow reserve >0.80) and a reduction of CFR and/or 245 
inducible microvascular spasm117, affects approximately 50% of patients with non-obstructive 246 
CAD or normal imaging findings118. Despite the absence of obstructive epicardial stenosis in 247 
these patients, they may present with severe myocardial ischemia (ischemia and non-248 
obstructive CAD, INOCA) or even MI (myocardial infarction and non-obstructive CAD, 249 
MINOCA). These conditions are more frequently observed in women, given the lower burden 250 
of obstructive CAD in the female population (Figure 2). In fact, the presence of microvascular 251 
angina is twice as prevalent in women than men118. The former portends a particularly high 252 
risk in women, as event-free survival is reduced in women with impaired CFR or coronary 253 
reactivity119, 120. As PET-derived CFR reflects the hemodynamic effects of focal, diffuse and 254 
microvascular CAD on myocardial tissue perfusion, impaired CFR seems to be an important 255 
target for CMVD risk reduction in women. Indeed, CMVD might also contribute to the 256 
pathogenesis of heart failure with preserved ejection fraction, another condition more 257 
commonly observed in women121. Thus, is it crucial that symptomatic patients who do not show 258 
regional ischemia associated with flow-limiting epicardial CAD undergo further testing. 259 
Although some studies demonstrate an improvement of prognosis by revascularization 260 
therapies (coronary artery bypass grafting, CABG) in patients with severely impaired CFR122, 261 
treatment of coronary microvascular disease (CMVD) usually includes standard anti-ischemic 262 
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drugs (β-blockers, angiotensin converting enzyme inhibitors, and nitrates). The diagnosis of 263 
CMVD requires a complex diagnostic work-up such as myocardial perfusion PET or invasive 264 
vasoreactivity testing; thus, optimal clinical assessment and pre-test risk stratification is crucial 265 
in order to avoid unnecessary costs and risk. In this regard, a blunted heart rate response 266 
during pharmacological stress testing has recently been shown to be a strong predictor of 267 
impaired CFR in women and may be a helpful marker to risk stratifies the heterogeneous 268 
population of patients with non-obstructive CAD15. 269 
 270 
Gender and Symptoms of Myocardial Ischemia 271 
Chest pain or pressure is the presenting symptom in >80% of women and men with ACS. 272 
However, women present with a greater number of additional non-chest pain symptoms than 273 
men such as neck pain, fatigue, dyspnea or nausea123. Further, women are more likely than 274 
men to present without chest pain and more often attribute their symptoms to a non-heart-275 
related condition such as acid reflux, stress or anxiety123. Also, women in general wait longer 276 
to seek medical attention and are less likely to have diagnostic electrocardiography changes 277 
and elevated troponin levels on admission124-126 (Figure 3). Accordingly, women are at an 278 
increased risk for an incorrect diagnosis and delayed treatment as evidenced by numerous 279 
studies reporting substantial system delays in women125-127. In addition, women who present 280 
with ACS tend to be older and have more comorbidities than their male counterparts128. Of 281 
note, however, young age and the absence of chest discomfort are among the strongest 282 
predictors of a missed diagnosis of ACS and inappropriate discharge from the emergency 283 
department129. Further, recent observational studies in younger demographic groups report a 284 
higher prevalence of comorbidities including depression, hypertension, diabetes, and obesity 285 
in younger women with ACS as compared to age-matched men, suggesting that gender-286 






Differential Diagnosis of ACS  291 
Contemporary strategies for managing patients presenting with typical or atypical symptoms, 292 
an abnormal electrocardiography and raised serum troponin presume a diagnosis of an acute 293 
type 1 MI. However, in up to 10% of all patients, and in up to one third of female patients, no 294 
culprit coronary lesion is identified angiographically131, 132. In these cases, the differential 295 
diagnosis includes apparently non-significant CAD such as plaque erosion, arrhythmias, 296 
coronary vasospasm (CVS), spontaneous coronary artery dissection (SCAD), Takotsubo 297 
cardiomyopathy, and myocarditis (Figure 3). While magnetic resonance imaging studies 298 
indicate that the latter seems to be present in the majority of cases where a culprit lesion is not 299 
identified133, a high index of suspicion for Takotsubo cardiomyopathy, CVS, and SCAD should 300 
be maintained when evaluating women134, 135. Takotsubo cardiomyopathy is characterized by 301 
transient left ventricular dysfunction resulting from severe emotional stress and usually 302 
resolves with a favorable prognosis. Although Takotsubo cardiomyopathy only accounts for up 303 
to 3% of all ACS cases, it is twice as prevalent in postmenopausal women134 (Figure 3).  304 
SCAD is an infrequent and often missed differential diagnosis of ACS and is 305 
characterized by a spontaneous separation of coronary arterial layers ultimately leading to 306 
intramural hematoma and impairment of anterograde coronary blood flow136. Recent 307 
epidemiological series suggest that SCAD occurs in 1–4% of ACS cases and may be the cause 308 
of ACS in up to 35% of women ≤50 years of age and in 43% of pregnancy-related ACS136 309 
(Figure 3). The latter is associated with a poorer prognosis than pregnancy-unrelated SCAD137. 310 
In-hospital mortality rates of SCAD are low, however, up to 14% of patients require urgent in-311 
hospital revascularization. Non-atherosclerotic SCAD is typically associated with female sex, 312 
multiparity, physical, and emotional stress triggers, systemic arteriopathies including 313 
fibromuscular dysplasia, inflammatory, and connective tissue disorders, coronary artery 314 
spasm, and hormonal therapy136. Although hormonal changes seem to play a major role in 315 
female SCAD, much remains to be explored on detailed molecular mechanisms by which sex 316 
hormones modulate arterial wall architecture and endothelial function. 317 
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CVS is caused by intense vasoconstriction of coronary arteries occurring most often 318 
at rest, particularly between midnight and early morning. Although the prognosis is generally 319 
considered benign, CVS can lead to total or subtotal vessel occlusion and subsequent ACS. 320 
CVS is diagnosed by coronary angiography and provocative testing and has been detected in 321 
49% of patients with ACS in a German population138. CVS appear to be more prevalent among 322 
men than women affecting mainly age groups between 40 and 70 years, and is more common 323 
in Asian populations as compared to Western countries139 (Figure 2). Vascular mechanisms 324 
triggering CVS episodes include transient sympatho-vagal imbalance as well as decreased 325 
bioavailability of vasodilators such as nitric oxide140, 141. Age, high-sensitivity C-reactive protein, 326 
and smoking have all been identified as significant risk predictors of CVS139. The latter has 327 
been suggested to account for the higher prevalence of CVS seen in men. 328 
 329 
Diagnosis and Disease Management of ACS 330 
Another issue remaining actively debated is whether there are still inequities in diagnosis and 331 
disease management, leading to gender-disparities in outcomes among patients with ACS. An 332 
excess risk for mortality in women with ACS, in particular for younger women, persists in 333 
contemporary practice142. Female coronary pathophysiology such as a higher prevalence of 334 
CMVD and non-obstructive CAD, atypical symptoms, delay in seeking care, underutilization of 335 
evidence-based diagnostics and therapies, and a higher rate of complications during 336 
revascularization have all been suggested to account for these findings. Indeed, management 337 
strategies for ACS have largely been the same for women and men while focused 338 
predominantly on obstructive CAD: risk stratification schemes for ACS including the HEART, 339 
the Global Registry of Acute Coronary Events (GRACE), and the Thrombolysis in Myocardial 340 
Infarction (TIMI) risk scores as well as the Killip classification are derived from predominantly 341 
male populations and their ability to adequately risk-stratify women with suspected ACS 342 
remains debatable143. Similarly, current clinical practice does not consider sex-specific cut-off 343 
values for cardiac troponin given the small differences in high sensitive troponin I between men 344 
and women. However, evidence demonstrates improved risk stratification in patients with ACS 345 
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when a sex-specific 99th centile threshold of high sensitive troponin I is being used144. Whether 346 
the lack of sex-specific guidelines or the high percentage of women presenting with atypical 347 
symptoms and comorbidities account for the fact that women are less likely than men to 348 
undergo invasive revascularization remains to be determined145, 146. In addition, low adherence 349 
to prescribed therapies as well as underutilization of cardiac rehabilitation and 350 
pharmacotherapies in women with ACS has also been reported147. Indeed, women are less 351 
likely than men to receive optimal secondary prevention with anti-platelet and lipid-lowering 352 
therapies even after angiographic documentation of disease146, 148, 149. These disparities persist 353 
in contemporary practice, despite studies documenting the reduction of this excess mortality 354 
when optimal care is provided150.  355 
 356 
Outcomes of ACS in Women and Men 357 
Short- and Long-term Mortality 358 
Although there is evidence that gender-disparities in short-term ACS mortality can be 359 
overcome in high-quality percutaneous coronary intervention (PCI) centers151, studies have 360 
consistently demonstrated less favorable short-term outcomes in women with ACS as 361 
compared to men, particularly after ST-elevation myocardial infarction (STEMI)1, 152, 153. The 362 
female susceptibility to adverse short-term outcomes following STEMI was attributed to their 363 
older age at presentation, the higher prevalence of comorbid conditions in women as well as 364 
longer system delays and underutilization of guideline-directed therapies in women with ACS 365 
150, 154, 155. Accordingly, sex and gender differences were attenuated when adjustment for 366 
comorbidities was performed156. In contrast to short-term outcomes, gender-specific data 367 
regarding long-term morbidity and mortality following ACS are conflicting. While long-term 368 
outcomes were similar for women and men in earlier studies, more recent work indicates that 369 
long-term morbidity and mortality following ACS is higher in women as compared to men, 370 
though these gender-disparities are no longer evident following adjustment for baseline 371 
variables157-159. Of note, however, studies report consistently worse short- and long-term 372 
outcomes in young and middle-aged women as compared to age-matched men160-163. As 373 
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previously discussed, this demographic group presents with an overall worse health status and 374 
encounters significant system delays and inequities in diagnosis and treatment, all of which 375 
might explain the excess risk in this population 4, 5, 164. 376 
 377 
Outcomes of Coronary Revascularization 378 
Current guidelines recommend immediate coronary angiography in patients with type 1 MI -379 
STEMI as well as in patients with type 1 MI - NSTEMI (Non ST-elevation myocardial infarction) 380 
presenting with refractory angina or electrical/hemodynamic instability independent of gender. 381 
An early invasive strategy (within 24 hours of diagnosis) is recommended for individuals with 382 
NSTEMI and stable clinical presentation but high-risk features according to current (gender-383 
unspecific) risk scores165, 166. Benefits of an early invasive strategy have been proven for both, 384 
men and women, while a very early invasive strategy within 12 hours of diagnosis improved 385 
outcomes in high-risk NSTEMI patients, but did not benefit women167, 168. Of note, despite an 386 
overall benefit of invasive revascularization, female sex has consistently been associated with 387 
an increased risk of bleeding and vascular complication during PCI169, 170 which underscores 388 
the need to consider key biological differences such as vessel size and prevalence of non-389 
obstructive CAD and to strictly apply guideline-directed care in women. Indeed, an increased 390 
risk of restenosis, repeat revascularization, and access-site complications in women 391 
attributable to their smaller coronary arteries and the frequent occurrence of radial artery 392 
vasospasm and subsequent radial-to-femoral access crossover all need to be taken into 393 
account when treatment decisions in women are made171, 172 (Figure 2 and 3).  394 
While there are currently no gender-specific data available on outcomes in patients 395 
with AMI unsuitable for PCI who undergo early CABG, observational studies report higher risks 396 
for short- and long-term mortality following CABG in women as compared to age-matched 397 
men, even when adjusted for age and comorbidities173-176. Instead, perioperative complications 398 
seem to be similar in women and men, except for a higher incidence of sternal wound infections 399 
in female patients177. Women’s smaller arteries and the challenges of surgical grafting to 400 
smaller targets, a longer cross-clamp time per graft, a lesser use of internal mammary artery 401 
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grafts in women, and a worse preoperative health status in women might all account for the 402 
gender differences in outcomes following CABG surgery. 403 
Importantly, recent studies report a significant increase in the incidence of ACS in 404 
pregnant women3. The latter is consistent with the recent rise seen in prevalence of CAD in 405 
younger, premenopausal women4, 5. According to latest European Society of Cardiology 406 
guidelines, primary PCI is recommended in pregnant patients with acute type I MI – STEMI 407 
consistent with standard indications for revascularization (class I recommendation), while a 408 
non-invasive approach is favored in stable, low-risk patients with type 1 MI - NSTEMI (class 409 
IIa recommendation)178. 410 
 411 
Risk of Thrombosis and Bleeding 412 
The risks of thrombosis and bleeding differ between men and women. These sex differences 413 
have been attributed to the higher age of women with ACS, comorbidities, and body weight179. 414 
In addition, women experience fluctuations of pro-thrombotic activity and hemostasis that are 415 
related to the menstrual cycle, the use of hormonal contraceptives or HRT, pregnancy, and 416 
menopause179, 180, all of which might contribute to sex differences in the thrombotic or 417 
hemorrhagic burden in women with ACS. Indeed, the higher risk of bleeding complications 418 
during PCI observed in women might in part be related to an estrogen-dependent increase of 419 
prostacyclin secretion and nitric oxide bioavailability as well as a direct inhibitory effect of 420 
estrogen on platelet aggregation181-184. Of note, however, there is conflicting evidence 421 
regarding sex differences in baseline and on-treatment platelet reactivity185-188. In fact, while 422 
some studies report a more pronounced platelet adhesion to the site of injury in men as 423 
compared to women189, others have demonstrated a greater baseline and agonist-induced 424 
platelet reactivity and aggregation in women181, 185, 190-192 (Figure 1). The latter contrasts with 425 
an up to 25% longer in vivo bleeding time in women as compared to men. Thus, further 426 
research is necessary to disentangle the complex interaction between hemostasis, sex, and 427 
hormone status at baseline and in the context of an ACS. In mainly postmenopausal cohorts, 428 
smaller arteries and related access-site complications as well as inappropriate dosing of anti-429 
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thrombotic agents irrespective of body weight have been suggested to account for their excess 430 
bleeding risk193. Indeed, female sex was associated with an enhanced risk of non-bypass-431 
related bleeding events in the prasugrel and ticagrelor arms of the TRITON-TIMI 38 and the 432 
PLATO trials194, 195. In contrast, no interaction between female sex and excess bleeding was 433 
seen in a meta-analysis comparing clopidogrel plus aspirin vs aspirin196, and a recent meta-434 
analysis reported a comparable efficacy and safety profile of potent P2Y12 inhibitors including 435 
prasugrel, ticagrelor, and intravenous cangrelor in women and men197. In contrast, however, 436 
recent data from the CRUSADE initiative indicate that women with type 1 MI - NSTEMI were 437 
more likely to receive excess glycoprotein (GP)IIb/IIIa doses than men, with the latter being 438 
associated with an increased risk of bleeding183. Taken together, these data indicate that sex 439 
should not influence patient selection for the administration of P2Y12 inhibitors; however, 440 
special attention has to be paid in women to properly apply weight- and age-adjustments of 441 
anti-thrombotic agents including GPIIb/IIIa inhibitors, heparins, and prasugrel. Indeed, up to 442 
one fourth of sex-related differences in bleeding risk seem to be avoidable183. 443 
As outlined above, a significant rise in the incidence of ACS is currently being 444 
observed in pregnant women3. Pregnancy is a pro-coagulant state, aimed at preventing 445 
bleeding at the time of delivery and is characterized by an increase in the levels of coagulation 446 
factors, fibrinogen, and von Willebrand factor, a reduction of activity of protein S and C, and 447 
an increase in plasminogen activator inhibitor type 1 and 2180. Unfortunately, current guidelines 448 
provide little information regarding the use of anti-platelet therapy in pregnant women with 449 
ACS. A recommendation is only given for aspirin, short-term heparinization during PCI and for 450 
clopidogrel, which should solely be used when strictly necessary and for the shortest duration. 451 
The use of GPIIb/IIIa inhibitors, bivalirudin, prasugrel, and ticagrelor is not recommended due 452 






Conclusion and Outlook 457 
Although substantial progress has been made towards improving gender- and sex-specific 458 
ACS disease management and outcomes, contemporary reports indicate a persistent 459 
knowledge gap with regard to optimal risk-stratification and management in female ACS 460 
patients. Prominent patient and system delays in women with AMI result from limited 461 
awareness for the latent CVD risk in women, a lack of sex-specific thresholds within clinical 462 
guidelines, and subsequent limited performance of contemporary diagnostic approaches in 463 
women, all of which are the result of a persistent underrepresentation of women in 464 
cardiovascular studies10. In addition, little is known about the influence of socio-environmental 465 
and contextual factors on gender-specific disease manifestation and outcomes. Thus, future 466 
research will have to overcome barriers accounting for the low numbers of women enrolled in 467 
ACS trials and to explore sex and gender differences in biology, environment, and 468 
psychosocial complexity. Finally, improved interdisciplinary and cooperative care in women’s 469 
health has recently been suggested as an attractive model to target cardiovascular health 470 
inequalities between women and men linked to modifiable risk factors and social determinants 471 
of health95. 472 
 473 
Figure Legend 474 
Figure 1: Effects of estrogen and testosterone on plaque development, atherothrombosis, 475 
coagulation, and vascular injury and healing. Evidence from experimental and clinical studies. 476 
LDL, low density lipoprotein; VSMC, vascular smooth muscle cell; EC, endothelial cell; CRP, 477 
c-reactive protein; TNF-α, tumor necrosis factor-α; IFNγ, interferon γ; IL, interleukin; CCL2, C-478 
C Motif chemokine ligand 2; F, factor; PAI-1, plasminogen activator inhibitor-1; eNOS, 479 
endothelial nitric oxide synthase; EDHF, endothelium-derived hyperpolarizing factor; PGI2, 480 
prostaglandin I2; ROS, reactive oxygen species; NADPH, nicotinamide adenine dinucleotide 481 
phosphate; VEGF, vascular endothelial growth factor; WBC, white blood cell; VCAM-1, 482 
vascular cell adhesion protein 1; TXA2, thromboxane A2; ADP, adenosine diphosphate; Bcl-483 
2, B-cell lymphoma 2 (inhibitor of apoptosis); STAT3, signal transducer and activator of 484 
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transcription 3; ATP, adenosine triphosphate. *Controversial data exist with regard to the effect 485 
of estrogen and testosterone on platelet aggregation responses and myocardial injury. 486 
Figure 2: Mechanisms and characteristics of myocardial ischemia in women and men. FFR, 487 
fractional flow reserve; INOCA, Ischemia and No Obstructive Coronary Artery Disease; 488 
MINOCA, Myocardial Infarction with No Obstructive Coronary Artery Disease.  489 
Figure 3: Sex differences in pathophysiology, presentation and outcomes of acute coronary 490 
syndromes (ACS). ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; 491 
PCI, percutaneous coronary intervention; SCAD, spontaneous coronary artery dissection. 492 
Figure 4: Sexually dimorphic epigenetic regulation of acute coronary syndrome (ACS). 493 
Potential sex-specific interplay between environmental changes, cardiovascular risk factors 494 
and epigenetic modifications (e.g. DNA methylation or histone modification) impacting 495 
atherosclerotic plaque development and cardiovascular risk during a lifetime. ACS, acute 496 
coronary syndrome; cRNA, coding RNA; DNA, deoxyribonucleic acid; miRNA, micro RNA; 497 
lncRNA, long non-coding RNA; RNA, ribonucleic acid. 498 
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